Toxic shock syndrome toxin 1 (TSST-1) is a 22-kDa exotoxin produced by strains of Staphylococcus aureus and implicated in the pathogenesis of toxic shock syndrome. In common with other staphylococcal exotoxins, TSST-1 has diverse immunological effects. These include the induction of interleukin 2 receptor expression, interleukin 2 synthesis, proliferation of human T lymphocytes, and stimulation of interleukin 1 synthesis by human monocytes. Toxic shock syndrome is a severe and often fatal disorder consistently associated with Staphylococcus aureus infection and characterized by multiple organ dysfunction (1-3). The exotoxin toxic shock syndrome toxin 1 (TSST-1) is a 22-kDa protein (4) produced by most strains of S. aureus isolated from patients with toxic shock syndrome (5, 6) and capable of inducing the disease in animal models (7). TSST-1 induces interleukin 1 synthesis by human monocytes (8, 9), accessory-cell-dependent proliferation of human T lymphocytes (10, 11), and the suppression of pokeweed mitogeninduced immunoglobulin synthesis by human lymphocytes (12). All three activities appear to reside in a 14-kDa internal toxin fragment and could not be dissected with multiple monoclonal antibodies (mAbs) (13, 14) . The identification of a cellular receptor for TSST-1 is important for the understanding of the mechanism of action of this toxin. TSST-1 has been reported to bind to cultured epithelial cells (15) and to T cells but not to monocytes or B cells (16) . To the best of our knowledge, the nature of the binding site has not been described. In the present study we demonstrate that TSST-1 binds to human major histocompatibility complex (MHC) class II molecules.
interleukin 2 receptor expression, interleukin 2 synthesis, proliferation of human T lymphocytes, and stimulation of interleukin 1 synthesis by human monocytes. In the present study, we demonstrate that TSST-1 binds with saturation kinetics and with a dissociation constant of 1743 nM to a single class of binding sites on human mononuclear cells. There was a strong correlation between the number of TSST-1 binding sites and the expression of major histocompatibility complex class II molecules, and interferon-v induced the expression of class H molecules as well as TSST-1 binding sites on human skin-derived fibroblasts. Monoclonal antibodies to HLA-DR, but not to HLA-DP or HLA-DQ, strongly inhibited TSST-1 binding. Affinity chromatography of '2I-labeled cell membranes over TSST-1-agarose resulted in the recovery of two bands of 35 kDa and 31 kDa that comigrated, respectively, with the a and fJ chains of HLA-DR and that could be immunoprecipitated with anti-HLA-DR monoclonal antibodies. Binding of TSST-1 was demonstrated to HLA-DR and HLA-DQ L-cell transfectants. These results indicate that major histocompatibility complex class H molecules represent the major binding site for TSST-1 on human cells.
Toxic shock syndrome is a severe and often fatal disorder consistently associated with Staphylococcus aureus infection and characterized by multiple organ dysfunction (1) (2) (3) . The exotoxin toxic shock syndrome toxin 1 (TSST-1) is a 22-kDa protein (4) produced by most strains of S. aureus isolated from patients with toxic shock syndrome (5, 6) and capable of inducing the disease in animal models (7) . TSST-1 induces interleukin 1 synthesis by human monocytes (8, 9) , accessory-cell-dependent proliferation of human T lymphocytes (10, 11) , and the suppression of pokeweed mitogeninduced immunoglobulin synthesis by human lymphocytes (12) . All three activities appear to reside in a 14-kDa internal toxin fragment and could not be dissected with multiple monoclonal antibodies (mAbs) (13, 14) .
The identification of a cellular receptor for TSST-1 is important for the understanding of the mechanism of action of this toxin. TSST-1 has been reported to bind to cultured epithelial cells (15) and to T cells but not to monocytes or B cells (16) . To the best of our knowledge, the nature of the binding site has not been described. In the present study we demonstrate that TSST-1 binds to human major histocompatibility complex (MHC) class II molecules.
MATERIALS AND METHODS Cell Preparations. Peripheral blood mononuclear cells (PBMCs) were isolated by standard methods (11) . Highly purified populations of T lymphocytes and monocytes were prepared as described (11, 17) . The preparation of B cells (18) from surgical specimens of human tonsil and of thymocytes (19) obtained from surgical specimens removed during open heart surgery were as described.
Normal human fibroblasts were grown from skin biopsies, propagated, and harvested as described (20) . Interferon y (IFN-y) treatment of fibroblasts was performed as described (20) , for 96 hr at 100 units/ml.
The T-cell lines Hut 78, Jurkat, and HPB-ALL and the histiocytic cell line U-937 were obtained from the American Type Culture Collection. The B-cell line Raji was a gift of A. Arnaout (Children's Hospital, Boston, MA). The B-cell line RPMI 8866 was a gift of K. Ishizaka (Johns Hopkins University, Baltimore, MD).
L-Cell Transfectants. The L-cell transfectants expressing HLA class II molecules used in this study were gifts of R. Karr (University of Iowa, IA) and were prepared by transfection of the respective full-length cDNA clones (DRa, DR4f3I, DPw4a, DPw4p, DQ7a, and DQw3,8) in the expression vector pcD together with the pSV2-neo plasmid into DAP.3 murine L-cell fibroblasts (21) . Cells were grown in tissue culture plates in complete RPMI 1640 medium containing G418 (250 jug/ml; GIBCO, Grand Island, NY) and were harvested by incubation for 15-20 min in isotonic phosphate-buffered saline (pH 7.4; PBS) containing 0.53 mM EDTA.
Toxins. TSST-1 was prepared as described (22) and iodinated using chloramine-T. determined from parallel tubes containing a 100-fold excess of unlabeled toxin. Antibodies. The following mAbs were used for immunoprecipitation and binding inhibition assays: the anti-DR mAb P4.1 (23), the anti-DR/DQ mAb ST2-59 (24) , and the anti-DP mAb B7/21. TSST-1 and BSA were each coupled to agarose (Affi-Gel 10, Bio-Rad) at 4°C with a protein/gel ratio of 2.5:1 (wt/vol). Aliquots of TSST-1-agarose and BSA-agarose were equilibrated with tetraethylammonium (TEA)/NaCl buffer (10 nM TEA/150 mM NaCI/1 mM EDTA) containing 0.5% Nonidet P-40 (NP-40) (Sigma). Cells were iodinated by the lactoperoxidase method, washed, and then lysed in 0.5 ml ofTEA/NaCI buffer containing 1% NP-40, 1 mM phenylmethylsulfonyl fluoride, and leupeptin (1 ug/ml), pepstatin (1 ,ug/ml), chymostatin (1 ,ug/ml), and antipain (1 ,ug/ml). The lysate was spun at 100,000 x g for 30 min, diluted with TEA/NaCl to a final concentration of 0.5% NP-40, precleared by three consecutive incubations with 150 ,ul of BSA-agarose, and then reacted with TSST-1-agarose or BSA-agarose (10-20 ,ul) for 4 hr. After extensive washing, TSST-1-binding proteins were eluted specifically by incubating the beads with soluble TSST-1 (25 ,ug in 25 ,ul of PBS/0.5% NP-40/1 mM phenylmethylsulfonyl fluoride) for 4 hr. The supernatants were then boiled with SDS sample buffer and subjected to SDS/PAGE on 12% polyacrylamide slab gels (26) . After drying, gels were exposed to Kodak XAR-5 film at -70°C with a DuPont intensifying screen for 2-7 days. Immunoprecipitation. Samples were incubated for 4-6 hr at 4°C with 25 ,ul (packed volume) of protein A-Sepharose (Pharmacia Fine Chemicals), 5-10 ,ug of specific mAb, and 10 ,ug of affinity-purified rabbit anti-mouse IgG (PelFreez, Rogers, AR). After incubation and washing, the beads were boiled in SDS sample buffer and eluted material was subjected to SDS/PAGE.
RESULTS
Characteristics of '25I-Labeled TSST-1 Binding to Target Cells. Initial binding studies were conducted on PBMCs and on the B-cell line RPMI 8866. The results on both cellular preparations were qualitatively similar. The time course of association of'25I-labeled TSST-1 (10 nM) to RPMI 8866 cells is illustrated in Fig. LA . The rate of specific binding at 4°C was rapid, with 50% of the equilibrium level being reached after 10 min of incubation. Equilibrium was reached within 1 hr of incubation. At 37°C, binding followed a similar time course initially but then showed a decline to a plateau that was TSST-1 (nM) We next examined the effect of the induction of MHC class II expression in fibroblasts on TSST-1 binding by these cells. Table 2 shows that treatment with IFN-y induced both the expression of MHC class II antigens and TSST-1 binding by fibroblasts.
The relationship between surface MHC class II molecules and TSST-1 binding sites was assessed by examining the effect of antibodies to MHC class II molecules on TSST-1 binding. We used for these experiments two cell lines, the B-cell line RPMI 8866 and the T-cell line HuT 78. Fig. 3 shows that both of these cell lines expressed HLA-DR, HLA-DP, and HLA-DQ on their surface. Anti-f32-microglobulin were seen under both reducing and nonreducing conditions (data not shown). The bands were not seen in the eluates of control BSA-agarose beads incubated with radiolabeled cell lysates under identical conditions (data not shown).
The relationship of the 31-kDa and 35-kDa bands of the TSST-1-binding protein to HLA-DR was investigated further by immunoprecipitation. TSST-1 eluates of the TSST-1-agarose, containing the 31-kDa and 35-kDa proteins, were subjected to immunoprecipitation with selected mAbs. As shown in Fig. 5 , the two bands were reprecipitated by the anti-HLA-DR mAb L243, but not by anti-HLA-DP or -DQ mAbs nor by the control mAb OKT11.
TSST-1 Binding to L-Cell Transfectants. Because HLA-DP and HLA-DQ were only weakly expressed compared to HLA-DR on the surface of the cell lines RPMI 8866 and HuT 78 (Fig. 3) , we could not rule out a role for these two molecules in TSST-1 binding. We, therefore, examined TSST-1 binding to mouse L-cell transfectants that expressed HLA-DR, HLA-DQ, or HLA-DP gene products. Immunofluorescence staining with anti-HLA-DR, HLA-DP, and HLA-DQ mAbs revealed comparable surface expression of the respective MHC class II antigens by each of the three transfectants. Table 4 shows the results of the TSST-1 binding assay on these cells. TSST-1 bound to the HLA-DR transfectant and to the HLA-DQ transfectant but not to the HLA-DP transfectant and not to untransfected L cells (data not shown).
DISCUSSION
The present study demonstrates that the bacterial toxin TSST-1 binds to MHC class II molecules on human cells.
The expression of TSST-1 binding sites on cells closely paralleled MHC class II antigen expression (Table 1) . More importantly, IFN-y treatment of fibroblasts induced in parallel the expression of MHC class II molecules and ofTSST-1 binding sites (Table 2) . TSST-1 binding showed saturability, reversibility, ligand specificity, and no evidence of cooperativity ( Figs. 1 and 2) . The dissociation constant of TSST-1 binding to various cells and cell lines fell within a narrow range (17-43 nM) that was comparable to the concentration range of TSST-1 (45-90 nM) that is optimal for the induction of proliferation of PBMCs (7) (8) (9) (10) . Several mAbs to HLA-DR inhibited TSST-1 binding to human cells (Table 3) , whereas anti-HLA-DP and anti-HLA-DQ mAbs failed to inhibit TSST-1 binding. This did not rule out involvement of HLA- (Fig. 3) . Inhibition of 125I-labeled TSST-1 binding by anti-HLA-DR mAbs was more effective (up to 80-90%) with the B-cell line RPMI 8866 than with the T-cell line HuT 78 (-50%, Table 3 ). Increasing the mAb concentration by 20-fold and/or combining two inhibitory mAbs did not increase the inhibition of 251I-labeled TSST-1 binding to HuT 78 above 60%o (data not shown). Neither the Scatchard analysis of binding data nor the affinity purification of the TSST-1 binding protein from HuT 78 (Fig. 4) support the existence of a second binding site for TSST-1. In view of data suggesting that clonally distributed T-cell receptors may recognize staphylococcal enterotoxin B on antigen-presenting cells (27, 28) , Ia-TSST-1 complexes on the T-cell line HuT 78 may be less accessible to displacement by anti-HLA-DR mAbs because of their interaction with a HuT 78-specific cell surface structure.
A heterodimer consisting of two radiolabeled bands, 35 kDa and 31 kDa, was isolated by affinity precipitation on TSST-1-agarose beads followed by ligand elution with TSST-1. These two bands comigrated with HLA-DR a and ,B (Fig.  4) and could be specifically immunoprecipitated by an anti-HLA-DR mAb from the material isolated on TSST-1-agarose (Fig. 5) . mAbs to HLA-DQ and HLA-DP did not immunoprecipitate these two bands, possibly because HLA-DP and HLA-DQ represent a relatively small fraction of the cell surface MHC class II molecules.
Because of the above limitation, we studied TSST-1 binding to MHC class II L-cell transfectants. Both the HLA-DR transfectant and the HLA-DQ transfectant bound TSST-1 (Table 4) whereas the HLA-DP transfectant did not. This clearly implicates HLA-DR and HLA-DQ molecules in TSST-1 binding and indicates that HLA-DP molecules such as DPw4a/DPw4/3 do not bind TSST-1. The present data do not, however, rule out a contribution of other cell surface proteins to TSST-1 binding by MHC class II molecules.
There is indirect evidence from functional studies to suggest that TSST-1 as well as the related staphylococcal enterotoxins A and B interact with MHC class II molecules. For all three toxins, the induction ofT-cell proliferation is dependent on the presence of Ia+ accessory cells (11, 27, 29) and does not require processing by the accessory cell. Toxin binding to Ia molecules may result in the transduction of a signal to the Ia+ cell, as suggested by the capacity of TSST-1 to induce interleukin 1 release by monocytes (7, 8) and to modulate B-cell function (12) . T cells may recognize a toxin-MHC class II complex or possibly only a multimeric form of the toxin. For staphylococcal enterotoxins A and B, the T-cell response to the toxin appears to be clonally distributed (27) . The nature of the T-cell receptor for TSST-1 and its relationship to the T-cell receptor for antigen remain to be determined.
